Arcus Biosciences Q2 FY26 net loss widens to USD 91 million; revenue drops 74.38% to USD 41 million

Reuters2026/08/05 20:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Arcus Biosciences posted a GAAP net loss of $91 million, or $0.72 a share, for Q2 2026.
Revenue fell 74.38% to $41 million versus Q2 2025, on a $143 million prior-year catch-up tied to pausing etrumadenant.
R&D expenses declined 18.71% to $113 million, while G&A costs dropped 17.24% to $24 million.
Cash, cash equivalents and marketable securities were $775 million at June 30; Arcus forecast roughly $600 million at end-2026.
Casdatifan ARC-20 readouts are due in H2 2026; Phase 3 PEAK-20 is expected to start by year-end, with cash runway into H2 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arcus Biosciences Inc. published the original content used to generate this news brief on August 05, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Arcus Biosciences Q2 FY26 net loss widens to USD 91 million; revenue drops 74.38% to USD 41 million

You may also like

Crypto prices